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We thank Drs Shibata-Hiraizumi and Suzuki 1 for their interest and informative comments on our recent article involving maternal ABO blood group and adverse pregnancy outcomes. 2 It was not our intention to include intrauterine fetal death as one of the outcomes because including both stillbirths and live births would constitute a heterogeneous population. This might influence the other outcomes. Furthermore, we were aware of the multifactorial etiology of intrauterine fetal death, for example, obstetric conditions, placental abnormalities, fetal genetic/structural abnormalities, infection, umbilical cord abnormalities, hypertensive disorders, unexplained cause, etc.
3 Table 1 . Adverse singleton pregnancy outcomes of the four groups in Japanese women according to their blood phenotypes Nevertheless, we were enthusiastic about their excellent comments and explored our database. We found that 23 women had intrauterine fetal death during the study period. Of these, 15 cases were obviously related to certain causes/conditions (8, 3, 2, 1 and 1 had fetal genetic/structural abnormalities, maternal diabetes, placental abruption, infection and umbilical cord accident, respectively). The number of gravidas who had unexplained fetal demise was only 8 (2, 3 and 3 had A, B and O blood types, respectively). This small number of cases did not merit our extended exploration of outcomes in relation to maternal blood group.
Finally, we absolutely agree with Drs Shibata-Hiraizumi and Suzuki that larger prospective studies in mixed or various population groups, but with strict inclusion criteria, are needed to assess more accurately the relationship between maternal ABO blood group and the risk of intrauterine fetal death. Paternal blood group should also be studied to determine whether it has an effect on this adverse outcome.
